טרוזה Израел - Хебрејски - Ministry of Health

טרוזה

dexcel ltd, israel - teriparatide - תמיסה להזרקה - teriparatide 250 mcg/ml - teriparatide

טריפראטייד קמהדע Израел - Хебрејски - Ministry of Health

טריפראטייד קמהדע

kamada ltd, israel - teriparatide - תמיסה להזרקה - teriparatide 0.250 mg / 1 ml - teriparatide

אלפא D 3 טיפות Израел - Хебрејски - Ministry of Health

אלפא d 3 טיפות

teva pharmaceutical industries ltd, israel - alfacalcidol - טיפות - alfacalcidol 0.25 mcg - alfacalcidol - alfacalcidol - renal bone disease. hypoparathyroidism. rickets and osteomalacia. osteoporosis. primary and tertiary hyperparathyroidism. neonatal hypocalcemia.

אלפא די 3 0.5 מק"ג Израел - Хебрејски - Ministry of Health

אלפא די 3 0.5 מק"ג

teva pharmaceutical indust.ltd - alfacalcidol 0.5 mcg - capsules - alfacalcidol - renal bone disease . hypoparathyroidisim. rickets and osteomalacia. osteoporosis. primary and tertiary hyperparathyroidism. neonatal hypocalcemia.

אלפא  די 3 0.25 מקג Израел - Хебрејски - Ministry of Health

אלפא די 3 0.25 מקג

truemed ltd, israel - alfacalcidol - קפסולות ג'לטין רכות - alfacalcidol 0.25 mcg - alfacalcidol - alfacalcidol - renal bone disease (renal osteodystrophy), hypoparathyroidism, hyperparathyroidism (with bone disease) - primary and tertiary. neonatal hypocalcemia, rickets and osteomalacia, osteoporosis.

טבאלפא די 3  0.25 מקג Израел - Хебрејски - Ministry of Health

טבאלפא די 3 0.25 מקג

teva pharmaceutical industries ltd, israel - alfacalcidol - קפסולות ג'לטין רכות - alfacalcidol 0.25 mcg - alfacalcidol - alfacalcidol - renal bone disease (renal osteodystrophy), hypoparathyroidism, hyperparathyroidism (with bone disease) - primary and tertiary. neonatal hypocalcemia, rickets and osteomalacia, osteoporosis.

אלפא די 3 1.0 מקג Израел - Хебрејски - Ministry of Health

אלפא די 3 1.0 מקג

truemed ltd, israel - alfacalcidol - קפסולות ג'לטין רכות - alfacalcidol 1 mcg - alfacalcidol - alfacalcidol - renal bone disease (renal osteodystrophy), hypoparathyroidism, hyperparathyroidism (with bone disease) - primary and tertiary. neonatal hypocalcemia, rickets and osteomalacia, osteoporosis.

טבאלפא 1.0 מקג Израел - Хебрејски - Ministry of Health

טבאלפא 1.0 מקג

teva pharmaceutical industries ltd, israel - alfacalcidol - קפסולות ג'לטין רכות - alfacalcidol 1 mcg - alfacalcidol - alfacalcidol - renal bone disease (renal osteodystrophy), hypoparathyroidism, hyperparathyroidism (with bone disease) - primary and tertiary. neonatal hypocalcemia, rickets and osteomalacia, osteoporosis.

אלפא די 3 1.0 מקג Израел - Хебрејски - Ministry of Health

אלפא די 3 1.0 מקג

teva pharmaceutical industries ltd, israel - alfacalcidol - קפסולות ג'לטין רכות - alfacalcidol 1 mcg - alfacalcidol - alfacalcidol - renal bone disease (renal osteodystrophy), hypoparathyroidism, hyperparathyroidism (with bone disease) - primary and tertiary. neonatal hypocalcemia, rickets and osteomalacia, osteoporosis.

פורטאו Израел - Хебрејски - Ministry of Health

פורטאו

eli lilly israel ltd, israel - teriparatide - תמיסה להזרקה - teriparatide 250 mcg/ml - teriparatide - teriparatide - treatment of postmenopausal women with osteoporosis at high risk for fracture:forteo is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. in postmenopausal women with osteoporosis, forteo increases bmd reduces the risk of vertebral and nonvertebral fractures . increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture :forteo is indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy . treatment of men and women with glucocorticoid-induced osteoporosis at high risk for fracture:forteo is indicated for the treatment of men and women with osteopo